More on BIOA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.90 |
|
|||
| Open | $21.90 | ||||
| 52 Wk High | $8.73 | ||||
| 52 Wk Low | $2.86 | ||||
| Day High | $22.32 | ||||
| Day Low | $21.35 | ||||
| P/E | N/A | ||||
| EPS | $-3.82 | ||||
| Volume | 1,031,115 | ||||
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA clears Leqembi Iqlik subcutaneous shot as Alzheimer's start dose
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- Form 4 BioAge Labs, Inc. For: Jun 29 Filed by: Barton Shane
- Form 144 BioAge Labs, Inc. Filed by: Barton Shane
- New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
- Form 144 BioAge Labs, Inc. Filed by: Barton Shane
- BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
- BioAge Labs begins Phase 2 trial of NLRP3 inhibitor BGE-102
Entities mentioned with BIOA
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- IPO | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Tesla | View Related Stories »
- Show More...
